#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Neurofunctional Differences Related to Methamphetamine and Sexual Cues in Men With Shorter and Longer Term Abstinence Methamphetamine Dependence Abstract Background Stimulant use and sexual behaviors have been linked in behavioral and epidemiological studies.
1-1	0-15	Neurofunctional	_
1-2	16-27	Differences	_
1-3	28-35	Related	_
1-4	36-38	to	_
1-5	39-54	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-6	55-58	and	_
1-7	59-65	Sexual	_
1-8	66-70	Cues	_
1-9	71-73	in	_
1-10	74-77	Men	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
1-11	78-82	With	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
1-12	83-90	Shorter	_
1-13	91-94	and	_
1-14	95-101	Longer	_
1-15	102-106	Term	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-16	107-117	Abstinence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-17	118-133	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-18	134-144	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
1-19	145-153	Abstract	_
1-20	154-164	Background	_
1-21	165-174	Stimulant	_
1-22	175-178	use	_
1-23	179-182	and	_
1-24	183-189	sexual	_
1-25	190-199	behaviors	_
1-26	200-204	have	_
1-27	205-209	been	_
1-28	210-216	linked	_
1-29	217-219	in	_
1-30	220-230	behavioral	_
1-31	231-234	and	_
1-32	235-250	epidemiological	_
1-33	251-258	studies	_
1-34	259-260	.	_

Text=Although methamphetamine-related neurofunctional differences have been investigated, few studies have examined neural responses to drug and sexual cues with respect to shorter or longer term methamphetamine abstinence in individuals with methamphetamine dependence.
2-1	261-269	Although	_
2-2	270-293	methamphetamine-related	_
2-3	294-309	neurofunctional	_
2-4	310-321	differences	_
2-5	322-326	have	_
2-6	327-331	been	_
2-7	332-344	investigated	_
2-8	345-346	,	_
2-9	347-350	few	_
2-10	351-358	studies	_
2-11	359-363	have	_
2-12	364-372	examined	_
2-13	373-379	neural	_
2-14	380-389	responses	_
2-15	390-392	to	_
2-16	393-397	drug	_
2-17	398-401	and	_
2-18	402-408	sexual	_
2-19	409-413	cues	_
2-20	414-418	with	_
2-21	419-426	respect	_
2-22	427-429	to	_
2-23	430-437	shorter	_
2-24	438-440	or	_
2-25	441-447	longer	_
2-26	448-452	term	_
2-27	453-468	methamphetamine	_
2-28	469-479	abstinence	_
2-29	480-482	in	_
2-30	483-494	individuals	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
2-31	495-499	with	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
2-32	500-515	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
2-33	516-526	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
2-34	527-528	.	_

Text=Methods Forty-nine men with shorter term methamphetamine abstinence, 50 men with longer term methamphetamine abstinence, and 47 non–drug-using healthy comparison men completed a functional magnetic resonance imaging cue-reactivity task consisting of methamphetamine, sexual, and neutral visual cues.
3-1	529-536	Methods	_
3-2	537-547	Forty-nine	_
3-3	548-551	men	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
3-4	552-556	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
3-5	557-564	shorter	_
3-6	565-569	term	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-7	570-585	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-8	586-596	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-9	597-598	,	_
3-10	599-601	50	_
3-11	602-605	men	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-12	606-610	with	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-13	611-617	longer	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-14	618-622	term	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-15	623-638	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-16	639-649	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
3-17	650-651	,	_
3-18	652-655	and	_
3-19	656-658	47	_
3-20	659-673	non–drug-using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-21	674-681	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-22	682-692	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-23	693-696	men	_
3-24	697-706	completed	_
3-25	707-708	a	_
3-26	709-719	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-27	720-728	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-28	729-738	resonance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-29	739-746	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-30	747-761	cue-reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-31	762-766	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-32	767-777	consisting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-33	778-780	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-34	781-796	methamphetamine	_
3-35	797-798	,	_
3-36	799-805	sexual	_
3-37	806-807	,	_
3-38	808-811	and	_
3-39	812-819	neutral	_
3-40	820-826	visual	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-41	827-831	cues	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-42	832-833	.	_

Text=Results Region-of-interest analyses revealed greater methamphetamine cue–related activation in shorter term methamphetamine abstinence and longer term methamphetamine abstinence individuals relative to healthy comparison men in the ventromedial prefrontal cortex.
4-1	834-841	Results	_
4-2	842-860	Region-of-interest	_
4-3	861-869	analyses	_
4-4	870-878	revealed	_
4-5	879-886	greater	_
4-6	887-902	methamphetamine	_
4-7	903-914	cue–related	_
4-8	915-925	activation	_
4-9	926-928	in	_
4-10	929-936	shorter	_
4-11	937-941	term	_
4-12	942-957	methamphetamine	_
4-13	958-968	abstinence	_
4-14	969-972	and	_
4-15	973-979	longer	_
4-16	980-984	term	_
4-17	985-1000	methamphetamine	_
4-18	1001-1011	abstinence	_
4-19	1012-1023	individuals	_
4-20	1024-1032	relative	_
4-21	1033-1035	to	_
4-22	1036-1043	healthy	_
4-23	1044-1054	comparison	_
4-24	1055-1058	men	_
4-25	1059-1061	in	_
4-26	1062-1065	the	_
4-27	1066-1078	ventromedial	_
4-28	1079-1089	prefrontal	_
4-29	1090-1096	cortex	_
4-30	1097-1098	.	_

Text=A significant interaction of group and condition in the anterior insula was found.
5-1	1099-1100	A	_
5-2	1101-1112	significant	_
5-3	1113-1124	interaction	_
5-4	1125-1127	of	_
5-5	1128-1133	group	_
5-6	1134-1137	and	_
5-7	1138-1147	condition	_
5-8	1148-1150	in	_
5-9	1151-1154	the	_
5-10	1155-1163	anterior	_
5-11	1164-1170	insula	_
5-12	1171-1174	was	_
5-13	1175-1180	found	_
5-14	1181-1182	.	_

Text=Relative to healthy comparison participants, both shorter term methamphetamine abstinence and longer term methamphetamine abstinence groups displayed greater sexual cue–related anterior insula activation relative to methamphetamine cues and neutral cues, but there were no differences between shorter term methamphetamine abstinence and longer term methamphetamine abstinence groups in anterior insula responses.
6-1	1183-1191	Relative	_
6-2	1192-1194	to	_
6-3	1195-1202	healthy	_
6-4	1203-1213	comparison	_
6-5	1214-1226	participants	_
6-6	1227-1228	,	_
6-7	1229-1233	both	_
6-8	1234-1241	shorter	_
6-9	1242-1246	term	_
6-10	1247-1262	methamphetamine	_
6-11	1263-1273	abstinence	_
6-12	1274-1277	and	_
6-13	1278-1284	longer	_
6-14	1285-1289	term	_
6-15	1290-1305	methamphetamine	_
6-16	1306-1316	abstinence	_
6-17	1317-1323	groups	_
6-18	1324-1333	displayed	_
6-19	1334-1341	greater	_
6-20	1342-1348	sexual	_
6-21	1349-1360	cue–related	_
6-22	1361-1369	anterior	_
6-23	1370-1376	insula	_
6-24	1377-1387	activation	_
6-25	1388-1396	relative	_
6-26	1397-1399	to	_
6-27	1400-1415	methamphetamine	_
6-28	1416-1420	cues	_
6-29	1421-1424	and	_
6-30	1425-1432	neutral	_
6-31	1433-1437	cues	_
6-32	1438-1439	,	_
6-33	1440-1443	but	_
6-34	1444-1449	there	_
6-35	1450-1454	were	_
6-36	1455-1457	no	_
6-37	1458-1469	differences	_
6-38	1470-1477	between	_
6-39	1478-1485	shorter	_
6-40	1486-1490	term	_
6-41	1491-1506	methamphetamine	_
6-42	1507-1517	abstinence	_
6-43	1518-1521	and	_
6-44	1522-1528	longer	_
6-45	1529-1533	term	_
6-46	1534-1549	methamphetamine	_
6-47	1550-1560	abstinence	_
6-48	1561-1567	groups	_
6-49	1568-1570	in	_
6-50	1571-1579	anterior	_
6-51	1580-1586	insula	_
6-52	1587-1596	responses	_
6-53	1597-1598	.	_

Text=Subsequent whole-brain analyses indicated a group-by-condition interaction with longer term methamphetamine abstinence participants showing greater sexual-related activation in the left superior frontal cortex relative to healthy comparison men.
7-1	1599-1609	Subsequent	_
7-2	1610-1621	whole-brain	_
7-3	1622-1630	analyses	_
7-4	1631-1640	indicated	_
7-5	1641-1642	a	_
7-6	1643-1661	group-by-condition	_
7-7	1662-1673	interaction	_
7-8	1674-1678	with	_
7-9	1679-1685	longer	_
7-10	1686-1690	term	_
7-11	1691-1706	methamphetamine	_
7-12	1707-1717	abstinence	_
7-13	1718-1730	participants	_
7-14	1731-1738	showing	_
7-15	1739-1746	greater	_
7-16	1747-1761	sexual-related	_
7-17	1762-1772	activation	_
7-18	1773-1775	in	_
7-19	1776-1779	the	_
7-20	1780-1784	left	_
7-21	1785-1793	superior	_
7-22	1794-1801	frontal	_
7-23	1802-1808	cortex	_
7-24	1809-1817	relative	_
7-25	1818-1820	to	_
7-26	1821-1828	healthy	_
7-27	1829-1839	comparison	_
7-28	1840-1843	men	_
7-29	1844-1845	.	_

Text=Shorter term methamphetamine abstinence participants showed greater superior frontal cortex activation to sexual relative to neutral cues, and longer term methamphetamine abstinence participants showed greater superior frontal cortex activation to sexual relative to neutral and methamphetamine cues.
8-1	1846-1853	Shorter	_
8-2	1854-1858	term	_
8-3	1859-1874	methamphetamine	_
8-4	1875-1885	abstinence	_
8-5	1886-1898	participants	_
8-6	1899-1905	showed	_
8-7	1906-1913	greater	_
8-8	1914-1922	superior	_
8-9	1923-1930	frontal	_
8-10	1931-1937	cortex	_
8-11	1938-1948	activation	_
8-12	1949-1951	to	_
8-13	1952-1958	sexual	_
8-14	1959-1967	relative	_
8-15	1968-1970	to	_
8-16	1971-1978	neutral	_
8-17	1979-1983	cues	_
8-18	1984-1985	,	_
8-19	1986-1989	and	_
8-20	1990-1996	longer	_
8-21	1997-2001	term	_
8-22	2002-2017	methamphetamine	_
8-23	2018-2028	abstinence	_
8-24	2029-2041	participants	_
8-25	2042-2048	showed	_
8-26	2049-2056	greater	_
8-27	2057-2065	superior	_
8-28	2066-2073	frontal	_
8-29	2074-2080	cortex	_
8-30	2081-2091	activation	_
8-31	2092-2094	to	_
8-32	2095-2101	sexual	_
8-33	2102-2110	relative	_
8-34	2111-2113	to	_
8-35	2114-2121	neutral	_
8-36	2122-2125	and	_
8-37	2126-2141	methamphetamine	_
8-38	2142-2146	cues	_
8-39	2147-2148	.	_

Text=Conclusions The findings suggest that abstinence from methamphetamine may alter how individuals respond to drug and sexual cues and thus may influence drug use and sexual behaviors.
9-1	2149-2160	Conclusions	_
9-2	2161-2164	The	_
9-3	2165-2173	findings	_
9-4	2174-2181	suggest	_
9-5	2182-2186	that	_
9-6	2187-2197	abstinence	_
9-7	2198-2202	from	_
9-8	2203-2218	methamphetamine	_
9-9	2219-2222	may	_
9-10	2223-2228	alter	_
9-11	2229-2232	how	_
9-12	2233-2244	individuals	_
9-13	2245-2252	respond	_
9-14	2253-2255	to	_
9-15	2256-2260	drug	_
9-16	2261-2264	and	_
9-17	2265-2271	sexual	_
9-18	2272-2276	cues	_
9-19	2277-2280	and	_
9-20	2281-2285	thus	_
9-21	2286-2289	may	_
9-22	2290-2299	influence	_
9-23	2300-2304	drug	_
9-24	2305-2308	use	_
9-25	2309-2312	and	_
9-26	2313-2319	sexual	_
9-27	2320-2329	behaviors	_
9-28	2330-2331	.	_

Text=Given the use of methamphetamine for sexual purposes and responses to natural vs drug rewards for addiction recovery, the findings may have particular clinical relevance.
10-1	2332-2337	Given	_
10-2	2338-2341	the	_
10-3	2342-2345	use	_
10-4	2346-2348	of	_
10-5	2349-2364	methamphetamine	_
10-6	2365-2368	for	_
10-7	2369-2375	sexual	_
10-8	2376-2384	purposes	_
10-9	2385-2388	and	_
10-10	2389-2398	responses	_
10-11	2399-2401	to	_
10-12	2402-2409	natural	_
10-13	2410-2412	vs	_
10-14	2413-2417	drug	_
10-15	2418-2425	rewards	_
10-16	2426-2429	for	_
10-17	2430-2439	addiction	_
10-18	2440-2448	recovery	_
10-19	2449-2450	,	_
10-20	2451-2454	the	_
10-21	2455-2463	findings	_
10-22	2464-2467	may	_
10-23	2468-2472	have	_
10-24	2473-2483	particular	_
10-25	2484-2492	clinical	_
10-26	2493-2502	relevance	_
10-27	2503-2504	.	_

Text=Methods Participants Participants were 146 men aged 19–45 years recruited from Hunan Province, China.
11-1	2505-2512	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	2513-2525	Participants	_
11-3	2526-2538	Participants	_
11-4	2539-2543	were	_
11-5	2544-2547	146	_
11-6	2548-2551	men	_
11-7	2552-2556	aged	_
11-8	2557-2562	19–45	_
11-9	2563-2568	years	_
11-10	2569-2578	recruited	_
11-11	2579-2583	from	_
11-12	2584-2589	Hunan	_
11-13	2590-2598	Province	_
11-14	2599-2600	,	_
11-15	2601-2606	China	_
11-16	2607-2608	.	_

Text=Individuals with a period of methamphetamine use more than 18 months before entering treatment and meeting the diagnosis criteria of methamphetamine dependence as determined by the Chinese version of the Structured Clinical Interview for Diagnosis and Statistical Manual of Mental Disorders were divided into 2 subsamples.
12-1	2609-2620	Individuals	_
12-2	2621-2625	with	_
12-3	2626-2627	a	_
12-4	2628-2634	period	_
12-5	2635-2637	of	_
12-6	2638-2653	methamphetamine	_
12-7	2654-2657	use	_
12-8	2658-2662	more	_
12-9	2663-2667	than	_
12-10	2668-2670	18	_
12-11	2671-2677	months	_
12-12	2678-2684	before	_
12-13	2685-2693	entering	_
12-14	2694-2703	treatment	_
12-15	2704-2707	and	_
12-16	2708-2715	meeting	_
12-17	2716-2719	the	_
12-18	2720-2729	diagnosis	_
12-19	2730-2738	criteria	_
12-20	2739-2741	of	_
12-21	2742-2757	methamphetamine	_
12-22	2758-2768	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
12-23	2769-2771	as	_
12-24	2772-2782	determined	_
12-25	2783-2785	by	_
12-26	2786-2789	the	_
12-27	2790-2797	Chinese	_
12-28	2798-2805	version	_
12-29	2806-2808	of	_
12-30	2809-2812	the	_
12-31	2813-2823	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-32	2824-2832	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-33	2833-2842	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-34	2843-2846	for	_
12-35	2847-2856	Diagnosis	_
12-36	2857-2860	and	_
12-37	2861-2872	Statistical	_
12-38	2873-2879	Manual	_
12-39	2880-2882	of	_
12-40	2883-2889	Mental	_
12-41	2890-2899	Disorders	_
12-42	2900-2904	were	_
12-43	2905-2912	divided	_
12-44	2913-2917	into	_
12-45	2918-2919	2	_
12-46	2920-2930	subsamples	_
12-47	2931-2932	.	_

Text=The LTMA (n = 50) sample was a convenience sample that was recruited from individuals scheduled for release from the Pingtang Isolated Compulsory Drug Rehabilitation Center, and the STMA (n = 49) sample was recruited from the Kangda Voluntary Drug Rehabilitation Center.
13-1	2933-2936	The	_
13-2	2937-2941	LTMA	_
13-3	2942-2943	(	_
13-4	2944-2945	n	_
13-5	2946-2947	=	_
13-6	2948-2950	50	_
13-7	2951-2952	)	_
13-8	2953-2959	sample	_
13-9	2960-2963	was	_
13-10	2964-2965	a	_
13-11	2966-2977	convenience	_
13-12	2978-2984	sample	_
13-13	2985-2989	that	_
13-14	2990-2993	was	_
13-15	2994-3003	recruited	_
13-16	3004-3008	from	_
13-17	3009-3020	individuals	_
13-18	3021-3030	scheduled	_
13-19	3031-3034	for	_
13-20	3035-3042	release	_
13-21	3043-3047	from	_
13-22	3048-3051	the	_
13-23	3052-3060	Pingtang	_
13-24	3061-3069	Isolated	_
13-25	3070-3080	Compulsory	_
13-26	3081-3085	Drug	_
13-27	3086-3100	Rehabilitation	_
13-28	3101-3107	Center	_
13-29	3108-3109	,	_
13-30	3110-3113	and	_
13-31	3114-3117	the	_
13-32	3118-3122	STMA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-33	3123-3124	(	_
13-34	3125-3126	n	_
13-35	3127-3128	=	_
13-36	3129-3131	49	_
13-37	3132-3133	)	_
13-38	3134-3140	sample	_
13-39	3141-3144	was	_
13-40	3145-3154	recruited	_
13-41	3155-3159	from	_
13-42	3160-3163	the	_
13-43	3164-3170	Kangda	_
13-44	3171-3180	Voluntary	_
13-45	3181-3185	Drug	_
13-46	3186-3200	Rehabilitation	_
13-47	3201-3207	Center	_
13-48	3208-3209	.	_

Text=The HC group (n = 47) was recruited from the local community.
14-1	3210-3213	The	_
14-2	3214-3216	HC	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
14-3	3217-3222	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
14-4	3223-3224	(	_
14-5	3225-3226	n	_
14-6	3227-3228	=	_
14-7	3229-3231	47	_
14-8	3232-3233	)	_
14-9	3234-3237	was	_
14-10	3238-3247	recruited	_
14-11	3248-3252	from	_
14-12	3253-3256	the	_
14-13	3257-3262	local	_
14-14	3263-3272	community	_
14-15	3273-3274	.	_

Text=Individuals were excluded for meeting criteria for Structured Clinical Interview for Diagnosis and Statistical Manual of Mental Disorders dependence on a substance other than nicotine (or for the methamphetamine groups, methamphetamine); the presence or history of a psychiatric disorder or general medical illness (e.g., cardiovascular disease, high blood pressure); a history of brain injury or loss consciousness of 10 minutes or more; left-handedness; and any contraindications of MRI scanning.
15-1	3275-3286	Individuals	_
15-2	3287-3291	were	_
15-3	3292-3300	excluded	_
15-4	3301-3304	for	_
15-5	3305-3312	meeting	_
15-6	3313-3321	criteria	_
15-7	3322-3325	for	_
15-8	3326-3336	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-9	3337-3345	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-10	3346-3355	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-11	3356-3359	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-12	3360-3369	Diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-13	3370-3373	and	_
15-14	3374-3385	Statistical	_
15-15	3386-3392	Manual	_
15-16	3393-3395	of	_
15-17	3396-3402	Mental	_
15-18	3403-3412	Disorders	_
15-19	3413-3423	dependence	_
15-20	3424-3426	on	_
15-21	3427-3428	a	_
15-22	3429-3438	substance	_
15-23	3439-3444	other	_
15-24	3445-3449	than	_
15-25	3450-3458	nicotine	_
15-26	3459-3460	(	_
15-27	3461-3463	or	_
15-28	3464-3467	for	_
15-29	3468-3471	the	_
15-30	3472-3487	methamphetamine	_
15-31	3488-3494	groups	_
15-32	3495-3496	,	_
15-33	3497-3512	methamphetamine	_
15-34	3513-3514	)	_
15-35	3515-3516	;	_
15-36	3517-3520	the	_
15-37	3521-3529	presence	_
15-38	3530-3532	or	_
15-39	3533-3540	history	_
15-40	3541-3543	of	_
15-41	3544-3545	a	_
15-42	3546-3557	psychiatric	_
15-43	3558-3566	disorder	_
15-44	3567-3569	or	_
15-45	3570-3577	general	_
15-46	3578-3585	medical	_
15-47	3586-3593	illness	_
15-48	3594-3595	(	_
15-49	3596-3600	e.g.	_
15-50	3601-3602	,	_
15-51	3603-3617	cardiovascular	_
15-52	3618-3625	disease	_
15-53	3626-3627	,	_
15-54	3628-3632	high	_
15-55	3633-3638	blood	_
15-56	3639-3647	pressure	_
15-57	3648-3649	)	_
15-58	3650-3651	;	_
15-59	3652-3653	a	_
15-60	3654-3661	history	_
15-61	3662-3664	of	_
15-62	3665-3670	brain	_
15-63	3671-3677	injury	_
15-64	3678-3680	or	_
15-65	3681-3685	loss	_
15-66	3686-3699	consciousness	_
15-67	3700-3702	of	_
15-68	3703-3705	10	_
15-69	3706-3713	minutes	_
15-70	3714-3716	or	_
15-71	3717-3721	more	_
15-72	3722-3723	;	_
15-73	3724-3739	left-handedness	_
15-74	3740-3741	;	_
15-75	3742-3745	and	_
15-76	3746-3749	any	_
15-77	3750-3767	contraindications	_
15-78	3768-3770	of	_
15-79	3771-3774	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
15-80	3775-3783	scanning	_
15-81	3784-3785	.	_

Text=All participants reported not having consumed alcohol or any other psychoactive substances for at least 48 hours before scanning, with corroborating information obtained from the doctors caring for the LTMA and STMA participants (as they were inpatients).
16-1	3786-3789	All	_
16-2	3790-3802	participants	_
16-3	3803-3811	reported	_
16-4	3812-3815	not	_
16-5	3816-3822	having	_
16-6	3823-3831	consumed	_
16-7	3832-3839	alcohol	_
16-8	3840-3842	or	_
16-9	3843-3846	any	_
16-10	3847-3852	other	_
16-11	3853-3865	psychoactive	_
16-12	3866-3876	substances	_
16-13	3877-3880	for	_
16-14	3881-3883	at	_
16-15	3884-3889	least	_
16-16	3890-3892	48	_
16-17	3893-3898	hours	_
16-18	3899-3905	before	_
16-19	3906-3914	scanning	_
16-20	3915-3916	,	_
16-21	3917-3921	with	_
16-22	3922-3935	corroborating	_
16-23	3936-3947	information	_
16-24	3948-3956	obtained	_
16-25	3957-3961	from	_
16-26	3962-3965	the	_
16-27	3966-3973	doctors	_
16-28	3974-3980	caring	_
16-29	3981-3984	for	_
16-30	3985-3988	the	_
16-31	3989-3993	LTMA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-32	3994-3997	and	_
16-33	3998-4002	STMA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-34	4003-4015	participants	_
16-35	4016-4017	(	_
16-36	4018-4020	as	_
16-37	4021-4025	they	_
16-38	4026-4030	were	_
16-39	4031-4041	inpatients	_
16-40	4042-4043	)	_
16-41	4044-4045	.	_

Text=The final participant sample of 146 individuals represents a total enrollment of 162 males, 155 of whom completed fMRI procedures, and the exclusion of 9 individuals for excessive head motion.
17-1	4046-4049	The	_
17-2	4050-4055	final	_
17-3	4056-4067	participant	_
17-4	4068-4074	sample	_
17-5	4075-4077	of	_
17-6	4078-4081	146	_
17-7	4082-4093	individuals	_
17-8	4094-4104	represents	_
17-9	4105-4106	a	_
17-10	4107-4112	total	_
17-11	4113-4123	enrollment	_
17-12	4124-4126	of	_
17-13	4127-4130	162	_
17-14	4131-4136	males	_
17-15	4137-4138	,	_
17-16	4139-4142	155	_
17-17	4143-4145	of	_
17-18	4146-4150	whom	_
17-19	4151-4160	completed	_
17-20	4161-4165	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
17-21	4166-4176	procedures	_
17-22	4177-4178	,	_
17-23	4179-4182	and	_
17-24	4183-4186	the	_
17-25	4187-4196	exclusion	_
17-26	4197-4199	of	_
17-27	4200-4201	9	_
17-28	4202-4213	individuals	_
17-29	4214-4217	for	_
17-30	4218-4227	excessive	_
17-31	4228-4232	head	_
17-32	4233-4239	motion	_
17-33	4240-4241	.	_

Text=A portion of the LTMA (n = 28) and HC (n = 27) was included in a previous report.
18-1	4242-4243	A	_
18-2	4244-4251	portion	_
18-3	4252-4254	of	_
18-4	4255-4258	the	_
18-5	4259-4263	LTMA	_
18-6	4264-4265	(	_
18-7	4266-4267	n	_
18-8	4268-4269	=	_
18-9	4270-4272	28	_
18-10	4273-4274	)	_
18-11	4275-4278	and	_
18-12	4279-4281	HC	_
18-13	4282-4283	(	_
18-14	4284-4285	n	_
18-15	4286-4287	=	_
18-16	4288-4290	27	_
18-17	4291-4292	)	_
18-18	4293-4296	was	_
18-19	4297-4305	included	_
18-20	4306-4308	in	_
18-21	4309-4310	a	_
18-22	4311-4319	previous	_
18-23	4320-4326	report	_
18-24	4327-4328	.	_

Text=All participants completed the Barratt Impulsiveness Scale (Chinese version).
19-1	4329-4332	All	_
19-2	4333-4345	participants	_
19-3	4346-4355	completed	_
19-4	4356-4359	the	_
19-5	4360-4367	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
19-6	4368-4381	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
19-7	4382-4387	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
19-8	4388-4389	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
19-9	4390-4397	Chinese	_
19-10	4398-4405	version	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionInstrument
19-11	4406-4407	)	_
19-12	4408-4409	.	_

Text=This study was approved by the ethical review board of the Second Xiangya Hospital of Central South University, which evaluated the study specifically related to participation of incarcerated individuals and conditions for use of incarcerated individuals in research were met.
20-1	4410-4414	This	_
20-2	4415-4420	study	_
20-3	4421-4424	was	_
20-4	4425-4433	approved	_
20-5	4434-4436	by	_
20-6	4437-4440	the	_
20-7	4441-4448	ethical	_
20-8	4449-4455	review	_
20-9	4456-4461	board	_
20-10	4462-4464	of	_
20-11	4465-4468	the	_
20-12	4469-4475	Second	_
20-13	4476-4483	Xiangya	_
20-14	4484-4492	Hospital	_
20-15	4493-4495	of	_
20-16	4496-4503	Central	_
20-17	4504-4509	South	_
20-18	4510-4520	University	_
20-19	4521-4522	,	_
20-20	4523-4528	which	_
20-21	4529-4538	evaluated	_
20-22	4539-4542	the	_
20-23	4543-4548	study	_
20-24	4549-4561	specifically	_
20-25	4562-4569	related	_
20-26	4570-4572	to	_
20-27	4573-4586	participation	_
20-28	4587-4589	of	_
20-29	4590-4602	incarcerated	_
20-30	4603-4614	individuals	_
20-31	4615-4618	and	_
20-32	4619-4629	conditions	_
20-33	4630-4633	for	_
20-34	4634-4637	use	_
20-35	4638-4640	of	_
20-36	4641-4653	incarcerated	_
20-37	4654-4665	individuals	_
20-38	4666-4668	in	_
20-39	4669-4677	research	_
20-40	4678-4682	were	_
20-41	4683-4686	met	_
20-42	4687-4688	.	_

Text=Participants from the compulsory and voluntary drug rehabilitation centers could decline involvement in the study if they had any concerns, and all participants provided voluntary written informed consent.
21-1	4689-4701	Participants	_
21-2	4702-4706	from	_
21-3	4707-4710	the	_
21-4	4711-4721	compulsory	_
21-5	4722-4725	and	_
21-6	4726-4735	voluntary	_
21-7	4736-4740	drug	_
21-8	4741-4755	rehabilitation	_
21-9	4756-4763	centers	_
21-10	4764-4769	could	_
21-11	4770-4777	decline	_
21-12	4778-4789	involvement	_
21-13	4790-4792	in	_
21-14	4793-4796	the	_
21-15	4797-4802	study	_
21-16	4803-4805	if	_
21-17	4806-4810	they	_
21-18	4811-4814	had	_
21-19	4815-4818	any	_
21-20	4819-4827	concerns	_
21-21	4828-4829	,	_
21-22	4830-4833	and	_
21-23	4834-4837	all	_
21-24	4838-4850	participants	_
21-25	4851-4859	provided	_
21-26	4860-4869	voluntary	_
21-27	4870-4877	written	_
21-28	4878-4886	informed	_
21-29	4887-4894	consent	_
21-30	4895-4896	.	_

Text=Cue-Reactivity Task The details for image selection and task design have been described previously.
22-1	4897-4911	Cue-Reactivity	_
22-2	4912-4916	Task	_
22-3	4917-4920	The	_
22-4	4921-4928	details	_
22-5	4929-4932	for	_
22-6	4933-4938	image	_
22-7	4939-4948	selection	_
22-8	4949-4952	and	_
22-9	4953-4957	task	_
22-10	4958-4964	design	_
22-11	4965-4969	have	_
22-12	4970-4974	been	_
22-13	4975-4984	described	_
22-14	4985-4995	previously	_
22-15	4996-4997	.	_

Text=Briefly, the 450-second cue-reactivity task consisted of 6 epochs, each containing three 20-second blocks (methamphetamine, sexual, and neutral images; Figure 1) and one 15-second rest (crosshair).
23-1	4998-5005	Briefly	_
23-2	5006-5007	,	_
23-3	5008-5011	the	_
23-4	5012-5022	450-second	_
23-5	5023-5037	cue-reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-6	5038-5042	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-7	5043-5052	consisted	_
23-8	5053-5055	of	_
23-9	5056-5057	6	_
23-10	5058-5064	epochs	_
23-11	5065-5066	,	_
23-12	5067-5071	each	_
23-13	5072-5082	containing	_
23-14	5083-5088	three	_
23-15	5089-5098	20-second	_
23-16	5099-5105	blocks	_
23-17	5106-5107	(	_
23-18	5108-5123	methamphetamine	_
23-19	5124-5125	,	_
23-20	5126-5132	sexual	_
23-21	5133-5134	,	_
23-22	5135-5138	and	_
23-23	5139-5146	neutral	_
23-24	5147-5153	images	_
23-25	5154-5155	;	_
23-26	5156-5162	Figure	_
23-27	5163-5164	1	_
23-28	5165-5166	)	_
23-29	5167-5170	and	_
23-30	5171-5174	one	_
23-31	5175-5184	15-second	_
23-32	5185-5189	rest	_
23-33	5190-5191	(	_
23-34	5192-5201	crosshair	_
23-35	5202-5203	)	_
23-36	5204-5205	.	_

Text=The methamphetamine cue-related images were the images of methamphetamine itself, people who were smoking methamphetamine, or the instruments they used to smoke methamphetamine.
24-1	5206-5209	The	_
24-2	5210-5225	methamphetamine	_
24-3	5226-5237	cue-related	_
24-4	5238-5244	images	_
24-5	5245-5249	were	_
24-6	5250-5253	the	_
24-7	5254-5260	images	_
24-8	5261-5263	of	_
24-9	5264-5279	methamphetamine	_
24-10	5280-5286	itself	_
24-11	5287-5288	,	_
24-12	5289-5295	people	_
24-13	5296-5299	who	_
24-14	5300-5304	were	_
24-15	5305-5312	smoking	_
24-16	5313-5328	methamphetamine	_
24-17	5329-5330	,	_
24-18	5331-5333	or	_
24-19	5334-5337	the	_
24-20	5338-5349	instruments	_
24-21	5350-5354	they	_
24-22	5355-5359	used	_
24-23	5360-5362	to	_
24-24	5363-5368	smoke	_
24-25	5369-5384	methamphetamine	_
24-26	5385-5386	.	_

Text=Each block contained 5 unique images presented for 3 seconds with a 1-second inter-stimulus interval.
25-1	5387-5391	Each	_
25-2	5392-5397	block	_
25-3	5398-5407	contained	_
25-4	5408-5409	5	_
25-5	5410-5416	unique	_
25-6	5417-5423	images	_
25-7	5424-5433	presented	_
25-8	5434-5437	for	_
25-9	5438-5439	3	_
25-10	5440-5447	seconds	_
25-11	5448-5452	with	_
25-12	5453-5454	a	_
25-13	5455-5463	1-second	_
25-14	5464-5478	inter-stimulus	_
25-15	5479-5487	interval	_
25-16	5488-5489	.	_

Text=Thus, a total 30 images of each cue condition (i.e., methamphetamine, sexual, and neutral) were presented during the fMRI scan.
26-1	5490-5494	Thus	_
26-2	5495-5496	,	_
26-3	5497-5498	a	_
26-4	5499-5504	total	_
26-5	5505-5507	30	_
26-6	5508-5514	images	_
26-7	5515-5517	of	_
26-8	5518-5522	each	_
26-9	5523-5526	cue	_
26-10	5527-5536	condition	_
26-11	5537-5538	(	_
26-12	5539-5543	i.e.	_
26-13	5544-5545	,	_
26-14	5546-5561	methamphetamine	_
26-15	5562-5563	,	_
26-16	5564-5570	sexual	_
26-17	5571-5572	,	_
26-18	5573-5576	and	_
26-19	5577-5584	neutral	_
26-20	5585-5586	)	_
26-21	5587-5591	were	_
26-22	5592-5601	presented	_
26-23	5602-5608	during	_
26-24	5609-5612	the	_
26-25	5613-5617	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
26-26	5618-5622	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
26-27	5623-5624	.	_

Text=The order of the images and the blocks within epochs were all presented pseudo-randomly to control for order effects across participants.
27-1	5625-5628	The	_
27-2	5629-5634	order	_
27-3	5635-5637	of	_
27-4	5638-5641	the	_
27-5	5642-5648	images	_
27-6	5649-5652	and	_
27-7	5653-5656	the	_
27-8	5657-5663	blocks	_
27-9	5664-5670	within	_
27-10	5671-5677	epochs	_
27-11	5678-5682	were	_
27-12	5683-5686	all	_
27-13	5687-5696	presented	_
27-14	5697-5712	pseudo-randomly	_
27-15	5713-5715	to	_
27-16	5716-5723	control	_
27-17	5724-5727	for	_
27-18	5728-5733	order	_
27-19	5734-5741	effects	_
27-20	5742-5748	across	_
27-21	5749-5761	participants	_
27-22	5762-5763	.	_

Text=fMRI Acquisition and Analysis Images were obtained using a 3.0-T Siemens scanner (Allegra; Siemens Medical System, Erlangen, Germany) equipped with a standard 20-channel head coil.
28-1	5764-5768	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-2	5769-5780	Acquisition	_
28-3	5781-5784	and	_
28-4	5785-5793	Analysis	_
28-5	5794-5800	Images	_
28-6	5801-5805	were	_
28-7	5806-5814	obtained	_
28-8	5815-5820	using	_
28-9	5821-5822	a	_
28-10	5823-5828	3.0-T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
28-11	5829-5836	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#2Level
28-12	5837-5844	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
28-13	5845-5846	(	_
28-14	5847-5854	Allegra	_
28-15	5855-5856	;	_
28-16	5857-5864	Siemens	_
28-17	5865-5872	Medical	_
28-18	5873-5879	System	_
28-19	5880-5881	,	_
28-20	5882-5890	Erlangen	_
28-21	5891-5892	,	_
28-22	5893-5900	Germany	_
28-23	5901-5902	)	_
28-24	5903-5911	equipped	_
28-25	5912-5916	with	_
28-26	5917-5918	a	_
28-27	5919-5927	standard	_
28-28	5928-5938	20-channel	_
28-29	5939-5943	head	_
28-30	5944-5948	coil	_
28-31	5949-5950	.	_

Text=Blood oxygen-level–dependent data were acquired with an echo-planar imaging sequence: repetition time (TR) = 2000 milliseconds, echo time (TE) = 30 milliseconds, flip = 80°, field of view = 220 × 220 mm, voxel size = 3.4 × 3.4 × 4.0 mm, slice thickness = 4 mm, gap = 1 mm, number of slices = 36.
29-1	5951-5956	Blood	_
29-2	5957-5979	oxygen-level–dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
29-3	5980-5984	data	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
29-4	5985-5989	were	_
29-5	5990-5998	acquired	_
29-6	5999-6003	with	_
29-7	6004-6006	an	_
29-8	6007-6018	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-9	6019-6026	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-10	6027-6035	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-11	6036-6037	:	_
29-12	6038-6048	repetition	_
29-13	6049-6053	time	_
29-14	6054-6055	(	_
29-15	6056-6058	TR	_
29-16	6059-6060	)	_
29-17	6061-6062	=	_
29-18	6063-6067	2000	_
29-19	6068-6080	milliseconds	_
29-20	6081-6082	,	_
29-21	6083-6087	echo	_
29-22	6088-6092	time	_
29-23	6093-6094	(	_
29-24	6095-6097	TE	_
29-25	6098-6099	)	_
29-26	6100-6101	=	_
29-27	6102-6104	30	_
29-28	6105-6117	milliseconds	_
29-29	6118-6119	,	_
29-30	6120-6124	flip	_
29-31	6125-6126	=	_
29-32	6127-6130	80°	_
29-33	6131-6132	,	_
29-34	6133-6138	field	_
29-35	6139-6141	of	_
29-36	6142-6146	view	_
29-37	6147-6148	=	_
29-38	6149-6152	220	_
29-39	6153-6154	×	_
29-40	6155-6158	220	_
29-41	6159-6161	mm	_
29-42	6162-6163	,	_
29-43	6164-6169	voxel	_
29-44	6170-6174	size	_
29-45	6175-6176	=	_
29-46	6177-6180	3.4	_
29-47	6181-6182	×	_
29-48	6183-6186	3.4	_
29-49	6187-6188	×	_
29-50	6189-6192	4.0	_
29-51	6193-6195	mm	_
29-52	6196-6197	,	_
29-53	6198-6203	slice	_
29-54	6204-6213	thickness	_
29-55	6214-6215	=	_
29-56	6216-6217	4	_
29-57	6218-6220	mm	_
29-58	6221-6222	,	_
29-59	6223-6226	gap	_
29-60	6227-6228	=	_
29-61	6229-6230	1	_
29-62	6231-6233	mm	_
29-63	6234-6235	,	_
29-64	6236-6242	number	_
29-65	6243-6245	of	_
29-66	6246-6252	slices	_
29-67	6253-6254	=	_
29-68	6255-6257	36	_
29-69	6258-6259	.	_

Text=The first 5 volumes (10 seconds) were removed from analyses to enable the signal to achieve steady-state equilibrium.
30-1	6260-6263	The	_
30-2	6264-6269	first	_
30-3	6270-6271	5	_
30-4	6272-6279	volumes	_
30-5	6280-6281	(	_
30-6	6282-6284	10	_
30-7	6285-6292	seconds	_
30-8	6293-6294	)	_
30-9	6295-6299	were	_
30-10	6300-6307	removed	_
30-11	6308-6312	from	_
30-12	6313-6321	analyses	_
30-13	6322-6324	to	_
30-14	6325-6331	enable	_
30-15	6332-6335	the	_
30-16	6336-6342	signal	_
30-17	6343-6345	to	_
30-18	6346-6353	achieve	_
30-19	6354-6366	steady-state	_
30-20	6367-6378	equilibrium	_
30-21	6379-6380	.	_

Text=Image analysis was performed using the Statistical Parametric Mapping 12 software package (SPM12, http: //www.fil.ion.ucl.ac.uk/spm/).
31-1	6381-6386	Image	_
31-2	6387-6395	analysis	_
31-3	6396-6399	was	_
31-4	6400-6409	performed	_
31-5	6410-6415	using	_
31-6	6416-6419	the	_
31-7	6420-6431	Statistical	_
31-8	6432-6442	Parametric	_
31-9	6443-6450	Mapping	_
31-10	6451-6453	12	_
31-11	6454-6462	software	_
31-12	6463-6470	package	_
31-13	6471-6472	(	_
31-14	6473-6478	SPM12	_
31-15	6479-6480	,	_
31-16	6481-6485	http	_
31-17	6486-6487	:	_
31-18	6488-6516	//www.fil.ion.ucl.ac.uk/spm/	_
31-19	6517-6518	)	_
31-20	6519-6520	.	_

Text=Functional images were realigned to the first volume of each session individually, normalized spatially into Montreal Neurological Institute template standardized space (resampling into 3 × 3 × 3 mm3 voxels), and smoothed with an 8-mm full-width-at-half-maximum Gaussian filter.
32-1	6521-6531	Functional	_
32-2	6532-6538	images	_
32-3	6539-6543	were	_
32-4	6544-6553	realigned	_
32-5	6554-6556	to	_
32-6	6557-6560	the	_
32-7	6561-6566	first	_
32-8	6567-6573	volume	_
32-9	6574-6576	of	_
32-10	6577-6581	each	_
32-11	6582-6589	session	_
32-12	6590-6602	individually	_
32-13	6603-6604	,	_
32-14	6605-6615	normalized	_
32-15	6616-6625	spatially	_
32-16	6626-6630	into	_
32-17	6631-6639	Montreal	_
32-18	6640-6652	Neurological	_
32-19	6653-6662	Institute	_
32-20	6663-6671	template	_
32-21	6672-6684	standardized	_
32-22	6685-6690	space	_
32-23	6691-6692	(	_
32-24	6693-6703	resampling	_
32-25	6704-6708	into	_
32-26	6709-6710	3	_
32-27	6711-6712	×	_
32-28	6713-6714	3	_
32-29	6715-6716	×	_
32-30	6717-6718	3	_
32-31	6719-6722	mm3	_
32-32	6723-6729	voxels	_
32-33	6730-6731	)	_
32-34	6732-6733	,	_
32-35	6734-6737	and	_
32-36	6738-6746	smoothed	_
32-37	6747-6751	with	_
32-38	6752-6754	an	_
32-39	6755-6759	8-mm	_
32-40	6760-6786	full-width-at-half-maximum	_
32-41	6787-6795	Gaussian	_
32-42	6796-6802	filter	_
32-43	6803-6804	.	_

Text=Participants (n = 9) were excluded from further analyses due to head motion in excess of 3 mm and/or 3°.
33-1	6805-6817	Participants	_
33-2	6818-6819	(	_
33-3	6820-6821	n	_
33-4	6822-6823	=	_
33-5	6824-6825	9	_
33-6	6826-6827	)	_
33-7	6828-6832	were	_
33-8	6833-6841	excluded	_
33-9	6842-6846	from	_
33-10	6847-6854	further	_
33-11	6855-6863	analyses	_
33-12	6864-6867	due	_
33-13	6868-6870	to	_
33-14	6871-6875	head	_
33-15	6876-6882	motion	_
33-16	6883-6885	in	_
33-17	6886-6892	excess	_
33-18	6893-6895	of	_
33-19	6896-6897	3	_
33-20	6898-6900	mm	_
33-21	6901-6907	and/or	_
33-22	6908-6910	3°	_
33-23	6911-6912	.	_

Text=A general linear model was used to conduct a functional data analysis.
34-1	6913-6914	A	_
34-2	6915-6922	general	_
34-3	6923-6929	linear	_
34-4	6930-6935	model	_
34-5	6936-6939	was	_
34-6	6940-6944	used	_
34-7	6945-6947	to	_
34-8	6948-6955	conduct	_
34-9	6956-6957	a	_
34-10	6958-6968	functional	_
34-11	6969-6973	data	_
34-12	6974-6982	analysis	_
34-13	6983-6984	.	_

Text=First-level models included each series of five 3-second pictures (1-second inter-stimulus interval) modeled as 20-second blocks by condition (methamphetamine, sexual, and neutral) and the 6 motion parameters as regressors.
35-1	6985-6996	First-level	_
35-2	6997-7003	models	_
35-3	7004-7012	included	_
35-4	7013-7017	each	_
35-5	7018-7024	series	_
35-6	7025-7027	of	_
35-7	7028-7032	five	_
35-8	7033-7041	3-second	_
35-9	7042-7050	pictures	_
35-10	7051-7052	(	_
35-11	7053-7061	1-second	_
35-12	7062-7076	inter-stimulus	_
35-13	7077-7085	interval	_
35-14	7086-7087	)	_
35-15	7088-7095	modeled	_
35-16	7096-7098	as	_
35-17	7099-7108	20-second	_
35-18	7109-7115	blocks	_
35-19	7116-7118	by	_
35-20	7119-7128	condition	_
35-21	7129-7130	(	_
35-22	7131-7146	methamphetamine	_
35-23	7147-7148	,	_
35-24	7149-7155	sexual	_
35-25	7156-7157	,	_
35-26	7158-7161	and	_
35-27	7162-7169	neutral	_
35-28	7170-7171	)	_
35-29	7172-7175	and	_
35-30	7176-7179	the	_
35-31	7180-7181	6	_
35-32	7182-7188	motion	_
35-33	7189-7199	parameters	_
35-34	7200-7202	as	_
35-35	7203-7213	regressors	_
35-36	7214-7215	.	_

Text=Given that prior findings showed no lateralized effects in cue reactivity in these regions, bilateral region-of-interest (ROI) was used in ROI analyses.
36-1	7216-7221	Given	_
36-2	7222-7226	that	_
36-3	7227-7232	prior	_
36-4	7233-7241	findings	_
36-5	7242-7248	showed	_
36-6	7249-7251	no	_
36-7	7252-7263	lateralized	_
36-8	7264-7271	effects	_
36-9	7272-7274	in	_
36-10	7275-7278	cue	_
36-11	7279-7289	reactivity	_
36-12	7290-7292	in	_
36-13	7293-7298	these	_
36-14	7299-7306	regions	_
36-15	7307-7308	,	_
36-16	7309-7318	bilateral	_
36-17	7319-7337	region-of-interest	_
36-18	7338-7339	(	_
36-19	7340-7343	ROI	_
36-20	7344-7345	)	_
36-21	7346-7349	was	_
36-22	7350-7354	used	_
36-23	7355-7357	in	_
36-24	7358-7361	ROI	_
36-25	7362-7370	analyses	_
36-26	7371-7372	.	_

Text=Bilateral ROIs were created using labeled regions of the Neuromorphometrics atlas (www.neuromorphometrics.com) for the ventral striatum using the accumbens area, for the dorsal striatum using the putamen and the caudate nucleus, for the vmPFC using the medial frontal cortex, and for the anterior insula using the anterior insula (supplemental Figure 1).
37-1	7373-7382	Bilateral	_
37-2	7383-7387	ROIs	_
37-3	7388-7392	were	_
37-4	7393-7400	created	_
37-5	7401-7406	using	_
37-6	7407-7414	labeled	_
37-7	7415-7422	regions	_
37-8	7423-7425	of	_
37-9	7426-7429	the	_
37-10	7430-7448	Neuromorphometrics	_
37-11	7449-7454	atlas	_
37-12	7455-7456	(	_
37-13	7457-7483	www.neuromorphometrics.com	_
37-14	7484-7485	)	_
37-15	7486-7489	for	_
37-16	7490-7493	the	_
37-17	7494-7501	ventral	_
37-18	7502-7510	striatum	_
37-19	7511-7516	using	_
37-20	7517-7520	the	_
37-21	7521-7530	accumbens	_
37-22	7531-7535	area	_
37-23	7536-7537	,	_
37-24	7538-7541	for	_
37-25	7542-7545	the	_
37-26	7546-7552	dorsal	_
37-27	7553-7561	striatum	_
37-28	7562-7567	using	_
37-29	7568-7571	the	_
37-30	7572-7579	putamen	_
37-31	7580-7583	and	_
37-32	7584-7587	the	_
37-33	7588-7595	caudate	_
37-34	7596-7603	nucleus	_
37-35	7604-7605	,	_
37-36	7606-7609	for	_
37-37	7610-7613	the	_
37-38	7614-7619	vmPFC	_
37-39	7620-7625	using	_
37-40	7626-7629	the	_
37-41	7630-7636	medial	_
37-42	7637-7644	frontal	_
37-43	7645-7651	cortex	_
37-44	7652-7653	,	_
37-45	7654-7657	and	_
37-46	7658-7661	for	_
37-47	7662-7665	the	_
37-48	7666-7674	anterior	_
37-49	7675-7681	insula	_
37-50	7682-7687	using	_
37-51	7688-7691	the	_
37-52	7692-7700	anterior	_
37-53	7701-7707	insula	_
37-54	7708-7709	(	_
37-55	7710-7722	supplemental	_
37-56	7723-7729	Figure	_
37-57	7730-7731	1	_
37-58	7732-7733	)	_
37-59	7734-7735	.	_

Text=For whole-brain analyses, a cluster-level familywise-error correction threshold of P <.05 was applied to the voxel-level uncorrected threshold of P <.01.
38-1	7736-7739	For	_
38-2	7740-7751	whole-brain	_
38-3	7752-7760	analyses	_
38-4	7761-7762	,	_
38-5	7763-7764	a	_
38-6	7765-7778	cluster-level	_
38-7	7779-7795	familywise-error	_
38-8	7796-7806	correction	_
38-9	7807-7816	threshold	_
38-10	7817-7819	of	_
38-11	7820-7821	P	_
38-12	7822-7823	<	_
38-13	7824-7827	.05	_
38-14	7828-7831	was	_
38-15	7832-7839	applied	_
38-16	7840-7842	to	_
38-17	7843-7846	the	_
38-18	7847-7858	voxel-level	_
38-19	7859-7870	uncorrected	_
38-20	7871-7880	threshold	_
38-21	7881-7883	of	_
38-22	7884-7885	P	_
38-23	7886-7887	<	_
38-24	7888-7891	.01	_
38-25	7892-7893	.	_

Text=Individual average parameter estimates within ROIs and whole brain–identified clusters were extracted for statistical analyses.
39-1	7894-7904	Individual	_
39-2	7905-7912	average	_
39-3	7913-7922	parameter	_
39-4	7923-7932	estimates	_
39-5	7933-7939	within	_
39-6	7940-7944	ROIs	_
39-7	7945-7948	and	_
39-8	7949-7954	whole	_
39-9	7955-7971	brain–identified	_
39-10	7972-7980	clusters	_
39-11	7981-7985	were	_
39-12	7986-7995	extracted	_
39-13	7996-7999	for	_
39-14	8000-8011	statistical	_
39-15	8012-8020	analyses	_
39-16	8021-8022	.	_

Text=Statistical Analysis Group-level ROI and whole-brain analyses were performed using 3 × 3 mixed-effects ANOVA with group (STMA, LTMA, HC) as a between-subjects factor, condition (methamphetamine, sexual, and neutral) as a within-subjects factor, and subject as a random-effects factor.
40-1	8023-8034	Statistical	_
40-2	8035-8043	Analysis	_
40-3	8044-8055	Group-level	_
40-4	8056-8059	ROI	_
40-5	8060-8063	and	_
40-6	8064-8075	whole-brain	_
40-7	8076-8084	analyses	_
40-8	8085-8089	were	_
40-9	8090-8099	performed	_
40-10	8100-8105	using	_
40-11	8106-8107	3	_
40-12	8108-8109	×	_
40-13	8110-8111	3	_
40-14	8112-8125	mixed-effects	_
40-15	8126-8131	ANOVA	_
40-16	8132-8136	with	_
40-17	8137-8142	group	_
40-18	8143-8144	(	_
40-19	8145-8149	STMA	_
40-20	8150-8151	,	_
40-21	8152-8156	LTMA	_
40-22	8157-8158	,	_
40-23	8159-8161	HC	_
40-24	8162-8163	)	_
40-25	8164-8166	as	_
40-26	8167-8168	a	_
40-27	8169-8185	between-subjects	_
40-28	8186-8192	factor	_
40-29	8193-8194	,	_
40-30	8195-8204	condition	_
40-31	8205-8206	(	_
40-32	8207-8222	methamphetamine	_
40-33	8223-8224	,	_
40-34	8225-8231	sexual	_
40-35	8232-8233	,	_
40-36	8234-8237	and	_
40-37	8238-8245	neutral	_
40-38	8246-8247	)	_
40-39	8248-8250	as	_
40-40	8251-8252	a	_
40-41	8253-8268	within-subjects	_
40-42	8269-8275	factor	_
40-43	8276-8277	,	_
40-44	8278-8281	and	_
40-45	8282-8289	subject	_
40-46	8290-8292	as	_
40-47	8293-8294	a	_
40-48	8295-8309	random-effects	_
40-49	8310-8316	factor	_
40-50	8317-8318	.	_

Text=ROI analyses and post-hoc testing of whole-brain findings were conducted with R. Post-hoc t tests were applied at a regional level to further investigate the nature of findings in regions demonstrating a main effect of group or an interaction of group by condition.
41-1	8319-8322	ROI	_
41-2	8323-8331	analyses	_
41-3	8332-8335	and	_
41-4	8336-8344	post-hoc	_
41-5	8345-8352	testing	_
41-6	8353-8355	of	_
41-7	8356-8367	whole-brain	_
41-8	8368-8376	findings	_
41-9	8377-8381	were	_
41-10	8382-8391	conducted	_
41-11	8392-8396	with	_
41-12	8397-8399	R.	_
41-13	8400-8408	Post-hoc	_
41-14	8409-8410	t	_
41-15	8411-8416	tests	_
41-16	8417-8421	were	_
41-17	8422-8429	applied	_
41-18	8430-8432	at	_
41-19	8433-8434	a	_
41-20	8435-8443	regional	_
41-21	8444-8449	level	_
41-22	8450-8452	to	_
41-23	8453-8460	further	_
41-24	8461-8472	investigate	_
41-25	8473-8476	the	_
41-26	8477-8483	nature	_
41-27	8484-8486	of	_
41-28	8487-8495	findings	_
41-29	8496-8498	in	_
41-30	8499-8506	regions	_
41-31	8507-8520	demonstrating	_
41-32	8521-8522	a	_
41-33	8523-8527	main	_
41-34	8528-8534	effect	_
41-35	8535-8537	of	_
41-36	8538-8543	group	_
41-37	8544-8546	or	_
41-38	8547-8549	an	_
41-39	8550-8561	interaction	_
41-40	8562-8564	of	_
41-41	8565-8570	group	_
41-42	8571-8573	by	_
41-43	8574-8583	condition	_
41-44	8584-8585	.	_

Text=One-way ANOVAs were performed to examine group differences within condition, and paired-samples t tests were performed in each group to assess condition effects.
42-1	8586-8593	One-way	_
42-2	8594-8600	ANOVAs	_
42-3	8601-8605	were	_
42-4	8606-8615	performed	_
42-5	8616-8618	to	_
42-6	8619-8626	examine	_
42-7	8627-8632	group	_
42-8	8633-8644	differences	_
42-9	8645-8651	within	_
42-10	8652-8661	condition	_
42-11	8662-8663	,	_
42-12	8664-8667	and	_
42-13	8668-8682	paired-samples	_
42-14	8683-8684	t	_
42-15	8685-8690	tests	_
42-16	8691-8695	were	_
42-17	8696-8705	performed	_
42-18	8706-8708	in	_
42-19	8709-8713	each	_
42-20	8714-8719	group	_
42-21	8720-8722	to	_
42-22	8723-8729	assess	_
42-23	8730-8739	condition	_
42-24	8740-8747	effects	_
42-25	8748-8749	.	_

Text=Subsequent analyses including age, education, tobacco use, and alcohol use as covariates were performed.
43-1	8750-8760	Subsequent	_
43-2	8761-8769	analyses	_
43-3	8770-8779	including	_
43-4	8780-8783	age	_
43-5	8784-8785	,	_
43-6	8786-8795	education	_
43-7	8796-8797	,	_
43-8	8798-8805	tobacco	_
43-9	8806-8809	use	_
43-10	8810-8811	,	_
43-11	8812-8815	and	_
43-12	8816-8823	alcohol	_
43-13	8824-8827	use	_
43-14	8828-8830	as	_
43-15	8831-8841	covariates	_
43-16	8842-8846	were	_
43-17	8847-8856	performed	_
43-18	8857-8858	.	_

Text=Relationships between brain activation and baseline methamphetamine use (i.e., duration [months] of methamphetamine use and dosage [grams] of methamphetamine use) and impulsivity scores were examined using Pearson correlations with a significance threshold of P <.05.
44-1	8859-8872	Relationships	_
44-2	8873-8880	between	_
44-3	8881-8886	brain	_
44-4	8887-8897	activation	_
44-5	8898-8901	and	_
44-6	8902-8910	baseline	_
44-7	8911-8926	methamphetamine	_
44-8	8927-8930	use	_
44-9	8931-8932	(	_
44-10	8933-8937	i.e.	_
44-11	8938-8939	,	_
44-12	8940-8948	duration	_
44-13	8949-8950	[	_
44-14	8951-8957	months	_
44-15	8958-8959	]	_
44-16	8960-8962	of	_
44-17	8963-8978	methamphetamine	_
44-18	8979-8982	use	_
44-19	8983-8986	and	_
44-20	8987-8993	dosage	_
44-21	8994-8995	[	_
44-22	8996-9001	grams	_
44-23	9002-9003	]	_
44-24	9004-9006	of	_
44-25	9007-9022	methamphetamine	_
44-26	9023-9026	use	_
44-27	9027-9028	)	_
44-28	9029-9032	and	_
44-29	9033-9044	impulsivity	_
44-30	9045-9051	scores	_
44-31	9052-9056	were	_
44-32	9057-9065	examined	_
44-33	9066-9071	using	_
44-34	9072-9079	Pearson	_
44-35	9080-9092	correlations	_
44-36	9093-9097	with	_
44-37	9098-9099	a	_
44-38	9100-9112	significance	_
44-39	9113-9122	threshold	_
44-40	9123-9125	of	_
44-41	9126-9127	P	_
44-42	9128-9129	<	_
44-43	9130-9133	.05	_
44-44	9134-9135	.	_

Text=A Bonferroni-correction for multiple comparisons threshold of P <(.05/4 = .0125) was applied.
45-1	9136-9137	A	_
45-2	9138-9159	Bonferroni-correction	_
45-3	9160-9163	for	_
45-4	9164-9172	multiple	_
45-5	9173-9184	comparisons	_
45-6	9185-9194	threshold	_
45-7	9195-9197	of	_
45-8	9198-9199	P	_
45-9	9200-9201	<	_
45-10	9202-9203	(	_
45-11	9204-9209	.05/4	_
45-12	9210-9211	=	_
45-13	9212-9217	.0125	_
45-14	9218-9219	)	_
45-15	9220-9223	was	_
45-16	9224-9231	applied	_
45-17	9232-9233	.	_

